Nintedanib (BIBF 1120) in Mesothelioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01907100
Recruitment Status : Completed
First Posted : July 24, 2013
Last Update Posted : September 11, 2018
Information provided by (Responsible Party):
Boehringer Ingelheim

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : March 16, 2018
  Actual Study Completion Date : August 28, 2018

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 September 11, 2018
(Canceled on September 27, 2018)
September 27, 2018